logoTry Persana

Lyell Immunopharma - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Lyell Immunopharma including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Lyell Immunopharma company logo

Advancing next-generation CAR T-cell therapies.

Lyell Immunopharma is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors and hematologic malignancies, utilizing innovative technologies to enhance cell therapy.

HeadquartersSouth San Francisco, United States
Team size200-300
FoundedNA

What is Lyell Immunopharma? - Company Overview & Details

Lyell Immunopharma is Lyell Immunopharma is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors and hematologic malignancies, utilizing innovative technologies to enhance cell therapy., the company is headquartered in South San Francisco, United States.

Who are the Key Executives at Lyell Immunopharma? - Leadership Team

Lyell Immunopharma is led by experienced executives in key positions:

Lyell Immunopharma Company Details & Key Information

Where is Lyell Immunopharma located?

Lyell Immunopharma is headquartered in South San Francisco, United States.

How many employees does Lyell Immunopharma have?

Lyell Immunopharma has 200-300 employees.

How much funding has Lyell Immunopharma raised?

Lyell Immunopharma has raised $493 million across 5 funding rounds. The most recent funding was completed on 2025-08-25.

Funding Overview

Lyell Immunopharma, a clinical-stage company specializing in CAR T-cell therapies, raised significant funding to support its ongoing clinical trials and operations.

$493 million
Total Funding Raised
5
Funding Rounds
2025-08-25
Latest Round

Lyell Immunopharma Funding History

Series C
2020-04-12
$493 million
Post IPO Equity
2025-08-25
$100 million

Who are the key investors in Lyell Immunopharma?

Investor Information Not Available

Detailed information about Lyell Immunopharma investors is not currently available in our database.

What are Lyell Immunopharma's future plans?

Lyell Immunopharma Lyell aims to scale its manufacturing capabilities and advance its clinical trials, especially for LYL314.

Lyell Immunopharma Strategic Outlook

Strategic Focus
Defined
3
Key Challenges
3
Growth Opportunities

What challenges does Lyell Immunopharma face?

Lyell Immunopharma has identified 3 key challenges that need to be addressed for continued growth and success.

Key Challenges for Lyell Immunopharma

1

Regulatory hurdles

2

Market competition

3

Funding requirements

What opportunities does Lyell Immunopharma have?

Lyell Immunopharma has identified 3 key opportunities for growth and market expansion.

Growth Opportunities for Lyell Immunopharma

1

Expansion of clinical trials

2

Potential partnerships for technology

3

Advancements in CAR T-cell therapies

Lyell Immunopharma Strategic Position Summary

Key Focus Areas

Lyell Immunopharma is addressing 3 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 3 key opportunities for expansion and growth.

What are the latest news about Lyell Immunopharma?

Lyell Immunopharma has 2 recent news updates covering key business developments and market activities.

Lyell Immunopharma News Overview

2
Recent Articles
Active
Media Coverage
2025-07-25
Latest Update

What is Lyell Immunopharma in the news for?

Lyell Immunopharma is currently featured in news for Lyell Immunopharma, Inc. received financing of $100M in equity private placement. and other significant business developments.

Recent News Articles About Lyell Immunopharma

Article 1
2025-07-25

Lyell Immunopharma, Inc. received financing of $100M in equity private placement.

Lyell Immunopharma announces up to $100 million equity private placement to fund pivotal-stage clinical trials.

globenewswire.com
Read News
Article 2
2025-06-09

Lyell Immunopharma, Inc. hired David Shook on Jun 9th '25.

Lyell Immunopharma strengthens its clinical and commercial capabilities with key Board and executive appointments.

globenewswire.com
Read News

Lyell Immunopharma FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Lyell Immunopharma including information about founders, CEO, funding history, investors, headquarters location, and company details. 11 frequently asked questions covering key information about the company.

Lyell Immunopharma Questions & Answers - Company Information

Q1

What is Lyell Immunopharma?

Lyell Immunopharma is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors and hematologic malignancies, utilizing innovative technologies to enhance cell therapy.

Q2

How much funding has Lyell Immunopharma raised?

Lyell Immunopharma has raised a total of $$493 million across 5 funding rounds. The most recent funding was completed on 2025-08-25.

Q3

Where is Lyell Immunopharma headquartered?

Lyell Immunopharma is headquartered in South San Francisco, United States.

Q4

How many employees does Lyell Immunopharma have?

Lyell Immunopharma has 200-300 employees.

Q5

What was Lyell Immunopharma's latest funding round?

Lyell Immunopharma's latest funding round was a Series C round of $$493 million completed on 2020-04-12.

Q6

What does the company do?

Lyell Immunopharma is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors and hematologic malignancies, utilizing innovative technologies to enhance cell therapy.

Q7

How much funding?

$493 million

Q8

Latest funding date?

2025-08-25

Q9

What are the challenges?

Regulatory hurdles Market competition Funding requirements

Q10

What are the opportunities?

Expansion of clinical trials Potential partnerships for technology Advancements in CAR T-cell therapies

Q11

Latest news?

Lyell Immunopharma announces up to $100 million equity private placement to fund pivotal-stage clinical trials. Lyell Immunopharma strengthens its clinical and commercial capabilities with key Board and executive appointments.

More Information About Lyell Immunopharma

For additional details about Lyell Immunopharma, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.